New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care for early and later stages of ADPKD in Europe and in various countries worldwide.
This is a preview of subscription content, log in via an institution to check access.
References
Ong, A. C., Devuyst, O., Knebelmann, B., Walz, G. & ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993–2002 (2015).
Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244–1252 (2014).
Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Mao, Z., Chong, J. & Ong, A. C. Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Res 5, 2029 (2016).
Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfx043 (2017).
Gansevoort, R. T. et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol. Dial. Transplant. 31, 337–348 (2016).
Devuyst, O. et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial. J. Am. Soc. Nephrol. 28, 1592–1602 (2017).
Torres, V. E. et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin. J. Am. Soc. Nephrol. 11, 803–811 (2016).
Grantham, J. J. & Torres, V. E. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat. Rev. Nephrol. 12, 667–677 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.C.M.O. was a site investigator in the TEMPO and REPRISE studies and has received research funding from Otsuka Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Ong, A. Tolvaptan slows disease progression in late-stage ADPKD. Nat Rev Nephrol 14, 146–148 (2018). https://doi.org/10.1038/nrneph.2017.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.180
- Springer Nature Limited